The LOI Is Not the Deal: The Chronological Anatomy of a 90-Day Enterprise Value Extraction

No matter how many transactions you watch, there is a pattern that never changes.

A seller signs a Letter of Intent. The headline number is 7x EBITDA. The broker sends congratulations. The seller tells their spouse they are retiring. Ninety days later, the wire hits the seller’s account and it is a million dollars short of the number they celebrated.

Nobody stole the money. Nobody committed fraud. The purchase agreement was executed exactly as written. Every reduction was contractually permitted, forensically documented, and procedurally legitimate.

The seller just did not know what was going to happen between Day 1 and Day 90.

This is the article I wish someone had written for every dentist who has ever signed an LOI. Not the legal overview. Not the broker’s FAQ. The actual chronological anatomy of what happens inside the 90-day extraction window and the specific mechanisms buyers use to move the number between the handshake and the wire.

---

The Chronological Anatomy of the 90-Day Extraction

Days 1-14: The Honeymoon and the Data Dump

The LOI is signed. The champagne popped. The broker celebrates the $4.2M headline valuation.

But buried in the LOI is the Exclusivity Clause. For the next 90 days, the seller is legally barred from speaking to any other buyer. They have surrendered their only leverage: the threat of walking away or running a competitive process.

On Day 3, the buyer’s Quality of Earnings team drops a 100+ item data request list. Five years of raw PMS data. Tax returns. Payroll registers. Bank statements. The seller’s team scrambles to compile it, while the buyer team offers to pull it for them. It’s assumed this is a formality to verify the broker’s prospectus.

It is not a formality. It is the beginning of a forensic extraction.

Days 15-45: The Black Box

Radio silence from the buyer. The seller assumes everything is fine.

It is not.

The buyer’s QoE team is not verifying the CPA’s math. They are running algorithms against the raw Dentrix or Eaglesoft database. They are mapping CDT utilization against payer industry benchmark databases. They are cross-referencing owner compensation against ADA Health Policy Institute benchmarks at the appropriate replacement-clinician percentile. They are hunting for Phantom EBITDA.

The buyer knows exactly what they are going to cut. They do not tell the seller yet. They wait for the exclusivity clock to tick down, increasing the seller’s deal fatigue and emotional commitment to closing.

Days 46-60: The Moment the Deal Changes

The QoE draft report lands. It does not look like the broker’s deck.

The buyer’s team systematically unwinds the seller’s add-backs. They reject the spouse’s salary add-back because she actually works in the practice — reception, three days a week, documented in payroll. That is not discretionary compensation. That is an operating expense a replacement owner would also incur.

They identify D4341 scaling and root planing utilization running 12% above national benchmarks for the patient demographic, with documentation gaps that would not survive a payor audit, and deduct the associated revenue from normalized EBITDA.

They reclassify the seller’s continuing education and conference travel ($38,000 annually) as a necessary operating expense rather than a discretionary add-back, arguing that any replacement clinician maintaining board certification would incur similar costs.

Each finding, individually, is defensible. Collectively, they remove $100,000 from the EBITDA baseline. At a 7x multiple, that is $700,000 in enterprise value that evaporates before anyone picks up the phone.

The buyer’s deal sponsor calls the seller. They are “disappointed” by what the QoE found. They still want to do the deal. But the math has to change.

Days 61-75: The Re-Trade

The buyer does not lower the multiple. They lower the EBITDA baseline.

This is the mechanism most sellers do not understand. The headline multiple stays at 7x — so the broker can still tell the seller they “held the multiple.” But $600,000 in normalized EBITDA is now $500,000. At 7x, $4.2M becomes $3.5M.

The seller is furious. But they are 70 days into exclusivity. They have already told their spouse, their office manager, and their associate. They have mentally and emotionally checked out of clinical operations. Walking away means restarting the process, 6 to 12 months of additional preparation, paying their broker and attorneys for a failed deal, and explaining to everyone why the retirement they announced is not happening.

The seller does the math on the cost of walking away. They accept the lower number.

Days 76-90: The Working Capital Trap and the Wire

The attorneys finalize the Asset Purchase Agreement. The seller thinks the bleeding has stopped.

Then the working capital peg is calculated.

At the closing table, the escrow holdback is locked away. The wire hits the seller’s account. It is over a million dollars short of the LOI headline. And the escrow they expect to recover in 24 months is already being underwritten against them.

---

The Working Capital Mechanism

The Working Capital Peg is the most misunderstood weapon in dental M&A.

Buyers require the seller to deliver the practice with enough working capital to operate on Day 1. They calculate the historical average working capital (current assets minus current liabilities), over the last 12 months. In our composite scenario, that average is $150,000.

But as the deal approaches, the seller naturally accelerates AR collection and delays paying bills to maximize their cash position at close. On closing day, the actual working capital delivered is $50,000. The buyer points to the $150,000 peg required by the LOI. The $100,000 deficit is deducted dollar-for-dollar from the seller’s cash at close.

The seller did not lose the money in operations. They collected it early. But the cash they thought they were receiving on top of the purchase price is gone.

Most sellers have never heard of a working capital peg before their attorney explains it to them on the day it is applied.

---

The Composite Scenario: A $1.05 Million Evaporation

This is a composite based on patterns I have observed across hundreds of transactions. The practice details are illustrative, but the mechanisms and math are real.

The Practice: $3M in collections. The broker claims $600,000 in normalized EBITDA.

The LOI: 7x multiple. Headline value: $4.2M.

The QoE Reduction: The buyer’s forensic team identifies $100K in non-compliant CDT coding, unverified add-backs, and reclassified expenses. Normalized EBITDA drops to $500,000.

The Re-Trade: At 7x, the new enterprise value is $3.5M. A $700,000 reduction from the headline.

The Working Capital Deduction: The seller accelerated AR collection pre-close. The buyer deducts $100,000 for the working capital deficit.

The Escrow Holdback: 10% of the revised purchase price — $350,000 — is held in escrow against future indemnification claims for 24 months.

Cash wired at close: $3.5M - $100K - $350K = $3.05M.

The Escrow Drawdown: Over the 24-month holdback period, the buyer draws down approximately $250,000 of the escrow. A patient complaint filed six months post-close. A payor audit triggered during re-credentialing. A lease renegotiation the buyer chose not to pursue. Each claim is individually small. Collectively, they consume the holdback. The seller eventually recovers $100,000 of the original $350,000 escrow.

Total realized value: $3.05M + $100K = $3.15M.

Milestone	Amount
Headline LOI value	$4,200,000
Post-QoE re-trade	-$700,000
Working capital deduction	-$100,000
Escrow holdback (locked at close)	-$350,000
Cash wired at close	$3,050,000
Escrow returned (24 months later)	+$100,000
Total realized value	$3,150,000
Total evaporation	$1,050,000

The seller celebrated a $4.2M exit. The wire at close came in at $3.05M. Twenty-four months later, after escrow drawdowns most sellers cannot effectively contest, the total realized value lands at $3.15M.

A $1.05 million evaporation. And the buyer used the seller’s own data to do it.

---

Why the Broker Cannot Save You

Brokers are compensated on a success fee tied to the close of the transaction. Their commission is calculated on the final purchase price — but their incentive is binary: the deal closes or it does not.

When the re-trade happens at Day 61, the broker’s calculation is straightforward. A $700,000 reduction in purchase price reduces their commission by a fraction of that amount. Walking away from the deal and starting over eliminates their commission entirely — plus the 6 to 12 months of work they have already invested.

The broker’s advice at the re-trade is almost always the same: take the deal. Not only because of the commission risk, but because the items that came up in due diligence won’t go away with another buyer.

This is not malice. It is incentive alignment. The broker is paid to close transactions, not to maximize the seller’s net proceeds. The seller needs someone in the room whose compensation is tied to the quality of the outcome, not just the fact of the outcome.

---

The 85% Statistic

According to SRS Acquiom’s 2025 M&A Deal Terms Study, 85% of lower-middle-market transactions face post-LOI purchase price adjustments after the buyer’s Quality of Earnings review.

That number is not driven by bad practices or bad brokers. It is the statistical baseline of what happens when a heavily capitalized forensic team examines financial data that was never designed to withstand forensic examination.

The 15% who do not get re-traded are not luckier. They are the sellers who ran their own forensic audit before the buyer ran theirs.

When a seller presents an LOI valuation based on independently verified, pre-normalized EBITDA — with every add-back substantiated, every CDT utilization rate benchmarked, every working capital exposure quantified — the buyer’s ability to execute a post-LOI re-trade is structurally crippled. They cannot claim to have “discovered” what the seller already identified, quantified, and disclosed.

The LOI is not the deal. It is the starting gun for a 90-day forensic extraction. The question is whether the seller enters that window with a defense already built — or whether they enters it with a champagne glass in one hand and a broker’s pitch deck in the other.